Ultra-long-acting analogues MAY BE CONSIDERED for basal insulin therapy in people at increased risk for hypoglycemia, as they are associated with a lower incidence of hypoglycemia and greater flexibility. This evidence concerns the gene INS and Hypoglycemia.